InvestorsHub Logo
Followers 51
Posts 9119
Boards Moderated 1
Alias Born 10/25/2007

Re: Gus1212 post# 670254

Tuesday, 02/06/2024 12:37:12 AM

Tuesday, February 06, 2024 12:37:12 AM

Post# of 705157
Another key part of Merck’s strategy is developing a subcutaneous, or under-the-skin, formulation of Keytruda, which is currently given intravenously. Such a version could give Merck leverage to compete with any generic versions of IV Keytruda that emerge following patent expiry in 2028.

https://www.biopharmadive.com/news/merck-dealmaking-15-billion-keytruda-cliff-davis/706309/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News